Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 98,424
  • Shares Outstanding, K 100,361
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,140 K
  • EBIT $ -25 M
  • EBITDA $ -25 M
  • 60-Month Beta 0.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.28
  • Most Recent Earnings $-0.10 on 11/12/25
  • Next Earnings Date 11/11/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8614 +15.17%
on 11/28/25
1.1500 -13.73%
on 11/12/25
-0.0179 (-1.77%)
since 11/05/25
3-Month
0.8614 +15.17%
on 11/28/25
1.5100 -34.30%
on 09/29/25
-0.0679 (-6.41%)
since 09/05/25
52-Week
0.3258 +204.51%
on 06/06/25
1.5100 -34.30%
on 09/29/25
+0.1271 (+14.69%)
since 12/05/24

Most Recent Stories

More News
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“ Oncolytics ” or the “ Company ”), a clinical-stage immunotherapy company developing pelareorep, today announced...

ONCY : 0.9921 (+1.16%)
Stocks in play: Oncolytics Biotech Inc

Announced alignment with the U.S. Food and Drug Administration regarding the design of its pivotal study ...

ONCY : 0.9921 (+1.16%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END

ONCY : 0.9921 (+1.16%)
IMRX : 6.40 (-4.33%)
ALXO : 1.4200 (+3.65%)
ERAS : 3.27 (+2.51%)
PRLD : 1.4600 (-5.19%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and...

ONCY : 0.9921 (+1.16%)
IMRX : 6.40 (-4.33%)
ALXO : 1.4200 (+3.65%)
ERAS : 3.27 (+2.51%)
PRLD : 1.4600 (-5.19%)
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

Company to launch only current registration trial with an immunotherapy in first-line pancreatic cancer in first half of 2026 Trial design allows flexibility to include...

ONCY : 0.9921 (+1.16%)
Stocks in play: Oncolytics Biotech Inc

Announced the formation of its Gastrointestinal Tumor Scientific Advisory Board (SAB), a group of leading ...

ONCY : 0.9921 (+1.16%)
Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy

Initial members include Dr. Sanjay Goel (Rutgers), Dr. Deva Mahalingam (Northwestern), and Dr. Dirk Arnold (GOBLET study; Asklepios Tumorzentrum Hamburg) Scientific Advisory...

ONCY : 0.9921 (+1.16%)
Stocks in play: Oncolytics Biotech Inc

Announced updated results from the single-arm squamous cell anal carcinoma cohort of the GOBLET study ...

ONCY : 0.9921 (+1.16%)
Stocks in play: Oncolytics Biotech Inc

Announced it has filed a registration statement on Form F-4 with the Securities and Exchange Commission ...

ONCY : 0.9921 (+1.16%)
Oncolytics Biotech Highlights Pelareorep’s Potential in Cancer Therapy

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Oncolytics...

ONCY : 0.9921 (+1.16%)

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 1.0781
2nd Resistance Point 1.0440
1st Resistance Point 1.0181
Last Price 0.9921
1st Support Level 0.9581
2nd Support Level 0.9240
3rd Support Level 0.8981

See More

52-Week High 1.5100
Fibonacci 61.8% 1.0576
Last Price 0.9921
Fibonacci 50% 0.9179
Fibonacci 38.2% 0.7782
52-Week Low 0.3258

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar